Electroretinographic findings in subjects after administration of fenretinide

Renee Krzeminski, Fred Zwas, Peggy Esper, Kenneth Pienta

Research output: Contribution to journalArticle

Abstract

We measured the electroretinogram to determine whether ocular toxicity exists in men taking oral fenretinide, 100 mg daily, for prevention of adenocarcinoma of the prostate. Male subjects at an increased risk for prostate cancer were recruited as volunteers. Fenretinide treatment took place over 1 year with a regimen of 100 mg/day for 25 days with 3 day hiatus intervals. Baseline testing included the electroretinogram Ishihara plates, and the Farnsworth-Munsell D-15 test. Subsequent electroretinographic testing was conducted at 4, 8, 12 and 18 months. Thirteen of 14 subjects maintained normal age-matched electroretinographic responses 6 months after fenretinide treatment. Of these 13 subjects, six showed slight decreases, within 1 standard deviation of the normal mean. Two subjects showed a slight gradual decline of rod-mediated a-wave amplitudes, while b-wave amplitudes were steady. One subject, who had glaucoma, unilaterally fell below normal. After treatment ended, all of the 13 subjects had electroretinographic responses at their respective baseline levels. The subject whose responses fell and remained below 1 standard deviation showed an overall decline in responses and, on follow-up, was diagnosed as having branch retinal vein occlusion, which most likely is the main contributor to the decrease in electroretinographic responses. Our results indicate that men taking 100 mg of oral fenretinide per day for 1 year, with a 3 day hiatus each month, do not show toxicity -induced retinal dysfunction, as measured by the electroretinogram.

Original languageEnglish (US)
Pages (from-to)299-309
Number of pages11
JournalDocumenta Ophthalmologica: The Journal of Clinical Electrophysiology and Vision - The Official Journal of the International Society for Clinical Electrophysiology and Vision
Volume91
Issue number4
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Fenretinide
Retinal Vein Occlusion
Glaucoma
Prostate
Volunteers
Prostatic Neoplasms
Adenocarcinoma
Therapeutics

Keywords

  • Adenocarcinoma
  • Electroretinogram
  • Fenretinide
  • Prostate
  • Retina
  • Retinoid

ASJC Scopus subject areas

  • Ophthalmology
  • Physiology (medical)
  • Sensory Systems

Cite this

@article{eededb9e10854582aa69954bca32ff53,
title = "Electroretinographic findings in subjects after administration of fenretinide",
abstract = "We measured the electroretinogram to determine whether ocular toxicity exists in men taking oral fenretinide, 100 mg daily, for prevention of adenocarcinoma of the prostate. Male subjects at an increased risk for prostate cancer were recruited as volunteers. Fenretinide treatment took place over 1 year with a regimen of 100 mg/day for 25 days with 3 day hiatus intervals. Baseline testing included the electroretinogram Ishihara plates, and the Farnsworth-Munsell D-15 test. Subsequent electroretinographic testing was conducted at 4, 8, 12 and 18 months. Thirteen of 14 subjects maintained normal age-matched electroretinographic responses 6 months after fenretinide treatment. Of these 13 subjects, six showed slight decreases, within 1 standard deviation of the normal mean. Two subjects showed a slight gradual decline of rod-mediated a-wave amplitudes, while b-wave amplitudes were steady. One subject, who had glaucoma, unilaterally fell below normal. After treatment ended, all of the 13 subjects had electroretinographic responses at their respective baseline levels. The subject whose responses fell and remained below 1 standard deviation showed an overall decline in responses and, on follow-up, was diagnosed as having branch retinal vein occlusion, which most likely is the main contributor to the decrease in electroretinographic responses. Our results indicate that men taking 100 mg of oral fenretinide per day for 1 year, with a 3 day hiatus each month, do not show toxicity -induced retinal dysfunction, as measured by the electroretinogram.",
keywords = "Adenocarcinoma, Electroretinogram, Fenretinide, Prostate, Retina, Retinoid",
author = "Renee Krzeminski and Fred Zwas and Peggy Esper and Kenneth Pienta",
year = "1995",
doi = "10.1007/BF01214648",
language = "English (US)",
volume = "91",
pages = "299--309",
journal = "Documenta Ophthalmologica",
issn = "0012-4486",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Electroretinographic findings in subjects after administration of fenretinide

AU - Krzeminski, Renee

AU - Zwas, Fred

AU - Esper, Peggy

AU - Pienta, Kenneth

PY - 1995

Y1 - 1995

N2 - We measured the electroretinogram to determine whether ocular toxicity exists in men taking oral fenretinide, 100 mg daily, for prevention of adenocarcinoma of the prostate. Male subjects at an increased risk for prostate cancer were recruited as volunteers. Fenretinide treatment took place over 1 year with a regimen of 100 mg/day for 25 days with 3 day hiatus intervals. Baseline testing included the electroretinogram Ishihara plates, and the Farnsworth-Munsell D-15 test. Subsequent electroretinographic testing was conducted at 4, 8, 12 and 18 months. Thirteen of 14 subjects maintained normal age-matched electroretinographic responses 6 months after fenretinide treatment. Of these 13 subjects, six showed slight decreases, within 1 standard deviation of the normal mean. Two subjects showed a slight gradual decline of rod-mediated a-wave amplitudes, while b-wave amplitudes were steady. One subject, who had glaucoma, unilaterally fell below normal. After treatment ended, all of the 13 subjects had electroretinographic responses at their respective baseline levels. The subject whose responses fell and remained below 1 standard deviation showed an overall decline in responses and, on follow-up, was diagnosed as having branch retinal vein occlusion, which most likely is the main contributor to the decrease in electroretinographic responses. Our results indicate that men taking 100 mg of oral fenretinide per day for 1 year, with a 3 day hiatus each month, do not show toxicity -induced retinal dysfunction, as measured by the electroretinogram.

AB - We measured the electroretinogram to determine whether ocular toxicity exists in men taking oral fenretinide, 100 mg daily, for prevention of adenocarcinoma of the prostate. Male subjects at an increased risk for prostate cancer were recruited as volunteers. Fenretinide treatment took place over 1 year with a regimen of 100 mg/day for 25 days with 3 day hiatus intervals. Baseline testing included the electroretinogram Ishihara plates, and the Farnsworth-Munsell D-15 test. Subsequent electroretinographic testing was conducted at 4, 8, 12 and 18 months. Thirteen of 14 subjects maintained normal age-matched electroretinographic responses 6 months after fenretinide treatment. Of these 13 subjects, six showed slight decreases, within 1 standard deviation of the normal mean. Two subjects showed a slight gradual decline of rod-mediated a-wave amplitudes, while b-wave amplitudes were steady. One subject, who had glaucoma, unilaterally fell below normal. After treatment ended, all of the 13 subjects had electroretinographic responses at their respective baseline levels. The subject whose responses fell and remained below 1 standard deviation showed an overall decline in responses and, on follow-up, was diagnosed as having branch retinal vein occlusion, which most likely is the main contributor to the decrease in electroretinographic responses. Our results indicate that men taking 100 mg of oral fenretinide per day for 1 year, with a 3 day hiatus each month, do not show toxicity -induced retinal dysfunction, as measured by the electroretinogram.

KW - Adenocarcinoma

KW - Electroretinogram

KW - Fenretinide

KW - Prostate

KW - Retina

KW - Retinoid

UR - http://www.scopus.com/inward/record.url?scp=0029495283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029495283&partnerID=8YFLogxK

U2 - 10.1007/BF01214648

DO - 10.1007/BF01214648

M3 - Article

C2 - 8899300

AN - SCOPUS:0029495283

VL - 91

SP - 299

EP - 309

JO - Documenta Ophthalmologica

JF - Documenta Ophthalmologica

SN - 0012-4486

IS - 4

ER -